TAKEDA PHARMACEUTICAL CO LTDTAKEarnings & Financial Report
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...
TAK Q1 FY2025 Key Financial Metrics
Revenue
$4.3M
Gross Profit
$2.8M
Operating Profit
$214.1K
Net Profit
$144.2K
Gross Margin
66.5%
Operating Margin
5.0%
Net Margin
3.4%
YoY Growth
N/A
TAKEDA PHARMACEUTICAL CO LTD Q1 FY2025 Financial Summary
TAKEDA PHARMACEUTICAL CO LTD reported revenue of $4.3M for Q1 FY2025, with a net profit of $144.2K (3.4% margin). Cost of goods sold was $1.4M, operating expenses totaled $2.6M.
Key Financial Metrics
| Total Revenue | $4.3M |
|---|---|
| Net Profit | $144.2K |
| Gross Margin | 66.5% |
| Operating Margin | 5.0% |
| Report Period | Q1 FY2025 |
TAKEDA PHARMACEUTICAL CO LTD Quarterly Revenue & Net Profit History
TAKEDA PHARMACEUTICAL CO LTD results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $4.3M | — | $144.2K | 3.4% |
| Q1 FY2024 | $4.0M | — | $317.0K | 7.9% |
Income Statement
| Q1 2024 | Q1 2025 | |
|---|---|---|
| Revenue | $4.0M | $4.3M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q1 2024 | Q1 2025 | |
|---|---|---|
| Assets | $98.21B | $92.61B |
| Liabilities | $50.93B | $47.53B |
| Equity | $47.28B | $45.08B |